Abbott Laboratories $ABT Shares Bought by Sivik Global Healthcare LLC

by · The Markets Daily

Sivik Global Healthcare LLC boosted its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 120.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 55,000 shares of the healthcare product maker’s stock after acquiring an additional 30,000 shares during the quarter. Abbott Laboratories comprises 3.4% of Sivik Global Healthcare LLC’s holdings, making the stock its 11th biggest position. Sivik Global Healthcare LLC’s holdings in Abbott Laboratories were worth $5,436,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $25,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories in the 4th quarter valued at $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in Abbott Laboratories in the 4th quarter valued at $26,000. Abound Financial LLC acquired a new stake in Abbott Laboratories during the 4th quarter worth $26,000. Finally, Manning & Napier Advisors LLC acquired a new stake in Abbott Laboratories during the 2nd quarter worth $31,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

ABT traded up $0.45 during trading on Tuesday, reaching $102.27. The company’s stock had a trading volume of 3,354,660 shares, compared to its average volume of 11,274,359. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The company’s fifty day moving average price is $106.14 and its 200-day moving average price is $98.29. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $133.34. The company has a market capitalization of $176.97 billion, a price-to-earnings ratio of 33.13, a price-to-earnings-growth ratio of 1.85 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Analyst Upgrades and Downgrades

A number of research firms have commented on ABT. TD Cowen restated a “buy” rating and issued a $135.00 price objective on shares of Abbott Laboratories in a research note on Tuesday, September 8th. BTIG Research upped their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a report on Friday, July 17th. Citigroup increased their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Barclays initiated coverage on Abbott Laboratories in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price target on the stock. Finally, Wells Fargo & Company increased their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $118.88.

View Our Latest Stock Report on Abbott Laboratories

About Abbott Laboratories

(Free Report)

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.

Further Reading

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).